Mahmoodi Nafiseh Sadat, Reza Okhovat Seyyed Ahmad, Reza Abtahi Seyyed Hamid, Moslehi Amirhossein
Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Adv Biomed Res. 2018 Feb 16;7:27. doi: 10.4103/2277-9175.225590. eCollection 2018.
Nasal corticosteroids are the main drug class for the treatment of allergic rhinitis, and their long-term continuous use can be problematic. The current study aimed to compare the use of Nasaleze and mometasone nasal spray in patients with allergic rhinitis.
In this study, 64 patients were studied in two groups of 32 patients. Nasaleze was used for the first group and mometasone for the second group for 4 weeks. The severity of sneezing, runny nose, tearing, nasal congestion, itchy eyes, and scratchy throat were evaluated at the onset of the study, and also 14 and 28 days after treatment in the form of a single-blind study. Statistical analysis was performed using SPSS Software (SPSS Inc., Chicago, IL, USA, Version 20).
The severity of allergic rhinitis symptoms had a significant difference in both groups of Nasaleze and mometasone at three times. Furthermore, in the Nasaleze group, the intensity of tearing significantly reduced 14 and 28 days after treatment compared to the mometasone group. In addition, the mean pretreatment score of allergic had no significant difference in the two groups neither14 days nor 28 days after the treatment.
The efficacy of Nasaleze nasal spray is very similar to that of mometasone nasal spray to control the symptoms of allergic rhinitis. Therefore, Nasaleze nasal spray can be a suitable alternative for nasal corticosteroids in children older than 18 months, pregnant and lactating women.
鼻用糖皮质激素是治疗变应性鼻炎的主要药物类别,长期持续使用可能存在问题。本研究旨在比较Nasaleze和莫米松鼻喷雾剂在变应性鼻炎患者中的应用。
本研究中,64例患者分为两组,每组32例。第一组使用Nasaleze,第二组使用莫米松,疗程4周。在研究开始时以及治疗后14天和28天,以单盲研究的形式评估打喷嚏、流鼻涕、流泪、鼻塞、眼痒和喉咙痒的严重程度。使用SPSS软件(美国伊利诺伊州芝加哥市SPSS公司,版本20)进行统计分析。
Nasaleze组和莫米松组在三个时间点变应性鼻炎症状的严重程度均有显著差异。此外,在Nasaleze组,与莫米松组相比,治疗后14天和28天流泪强度显著降低。另外,两组治疗前变应性平均评分在治疗后14天和28天均无显著差异。
Nasaleze鼻喷雾剂在控制变应性鼻炎症状方面的疗效与莫米松鼻喷雾剂非常相似。因此,Nasaleze鼻喷雾剂可作为18个月以上儿童、孕妇和哺乳期妇女鼻用糖皮质激素的合适替代品。